View source for Template:Relative affinities of norethisterone, metabolites, and prodrugs

{| class="wikitable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Relative affinities of norethisterone, metabolites, and prodrugs|mini=y}} Relative affinities (%) of {{No selflink|norethisterone}}, metabolites, and prodrugs
|-
! Compound !! Type<sup>a</sup> !! {{abbrlink|PR|Progesterone receptor}} !! {{abbrlink|AR|Androgen receptor}} !! {{abbrlink|ER|Estrogen receptor}} !! {{abbrlink|GR|Glucocorticoid receptor}} !! {{abbrlink|MR|Mineralocorticoid receptor}} !! {{abbrlink|SHBG|Sex hormone-binding globulin}} !! {{abbrlink|CBG|Corticosteroid binding globulin}}
|-
| {{No selflink|Norethisterone}} || – || 67–75 || 15 || 0 || 0–1 || 0–3 || 16 || 0
|-
| style="padding-left:1.5em;" | {{No selflink|5α-Dihydronorethisterone}} || Metabolite || 25 || 27 || 0 || 0 || ? || ? || ?
|-
| style="padding-left:1.5em;" | 3α,5α-Tetrahydronorethisterone || Metabolite || 1 || 0 || 0–1 || 0 || ? || ? || ?
|-
| style="padding-left:1.5em;" | 3α,5β-Tetrahydronorethisterone || Metabolite || ? || 0 || 0 || ? || ? || ? || ?
|-
| style="padding-left:1.5em;" | 3β,5α-Tetrahydronorethisterone || Metabolite || 1 || 0 || 0–8 || 0 || ? || ? || ?
|-
| style="padding-left:1.5em;" | {{No selflink|Ethinylestradiol}} || Metabolite || 15–25 || 1–3 || 112 || 1–3 || 0 || 0.18 || 0
|-
| {{No selflink|Norethisterone acetate}} || Prodrug || 20 || 5 || 1 || 0 || 0 || ? || ?
|-
| {{No selflink|Norethisterone enanthate}} || Prodrug || ? || ? || ? || ? || ? || ? || ?
|-
| {{No selflink|Noretynodrel}} || Prodrug || 6 || 0 || 2 || 0 || 0 || 0 || 0
|-
| {{No selflink|Etynodiol}} || Prodrug || 1 || 0 || 11–18 || 0 || ? || ? || ?
|-
| {{No selflink|Etynodiol diacetate}} || Prodrug || 1 || 0 || 0 || 0 || 0 || ? || ?
|-
| {{No selflink|Lynestrenol}} || Prodrug || 1 || 1 || 3 || 0 || 0 || ? || ?
|-
| colspan="9" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Notes:''' Values are percentages (%). Reference [[Biology:Ligand (biochemistry)|ligand]]s (100%) were [[Chemistry:Promegestone|promegestone f]]or the {{abbrlink|PR|progesterone receptor}}, [[Chemistry:Metribolone|metribolone f]]or the {{abbrlink|AR|androgen receptor}}, [[Chemistry:Estradiol (medication)|estradiol]] for the {{abbrlink|ER|estrogen receptor}}, [[Biology:Dexamethasone|dexamethasone]] for the {{abbrlink|GR|glucocorticoid receptor}}, [[Chemistry:Aldosterone|aldosterone]]]] for the {{abbrlink|MR|mineralocorticoid receptor}}, [[Chemistry:Androstanolone|dihydrotestosterone]] for {{abbrlink|SHBG|sex hormone-binding globulin}}, and [[Chemistry:Hydrocortisone|cortisol]] for {{abbrlink|CBG|Corticosteroid-binding globulin}}. '''Footnotes:''' <sup>a</sup> = [[Biology:Active metabolite|Active]]]] or inactive [[Biology:Metabolite|metabolite]], [[Chemistry:Prodrug|prodrug]], or neither of norethisterone. '''Sources:''' <noinclude><ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | issue = | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}</ref><ref name="pmid2170822">{{cite journal | vauthors = Kuhl H | title = Pharmacokinetics of oestrogens and progestogens | journal = Maturitas | volume = 12 | issue = 3 | pages = 171–97 | date = September 1990 | pmid = 2170822 | doi = 10.1016/0378-5122(90)90003-O | url = }}</ref><ref name="pmid10599548">{{cite journal | vauthors = Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M | title = The pharmacological profile of a novel norpregnance progestin (trimegestone) | journal = Gynecol. Endocrinol. | volume = 13 | issue = 5 | pages = 316–26 | date = October 1999 | pmid = 10599548 | doi = 10.3109/09513599909167574 | url = }}</ref><ref name="RaynaudOjasoo1979">{{cite book|last1=Raynaud|first1=J.P.|last2=Ojasoo|first2=T.|last3=Bouton|first3=M.M.|last4=Philibert|first4=D.|chapter=Receptor Binding as a Tool in the Development of New Bioactive Steroids|year=1979|pages=169–214|doi=10.1016/B978-0-12-060308-4.50010-X|title=Drug Design: Medicinal Chemistry: A Series of Monographs|volume=8|url=https://books.google.com/books?id=bhAlBQAAQBAJ&pg=PA169|isbn=978-0120603084}}</ref><ref name="pmid7195405">{{cite journal | vauthors = Pugeat MM, Dunn JF, Nisula BC | title = Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma | journal = J. Clin. Endocrinol. Metab. | volume = 53 | issue = 1 | pages = 69–75 | date = July 1981 | pmid = 7195405 | doi = 10.1210/jcem-53-1-69 | url = }}</ref></noinclude><includeonly>See template.</includeonly>
|}<!--

--><noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>